A phase 1 study of 7MW3711 advanced solid tumors patients
Latest Information Update: 25 Jul 2023
At a glance
- Drugs 7MW 3711 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 21 Jul 2023 According to a Mabwell Therapeutics Media Release, clinical trial application of 7MW3711 for advanced malignant solid tumor was approved by the National Medical Products Administration (NMPA).
- 25 May 2023 New trial record